Prognostic Evaluation Prediction Model Survival Spinal Epidural Metastases

NCT06411015 | Completed

• 1 other identifier: Radboudumcnch001
• Study Type: observational
• Target: 428
• Locations: 1 country
• Sites: 1

Brief Summary

Patients with symptomatic spinal metatstasis will be prosepectively included in a database after theu signes informed consent. Minimally six months after inclusion the survival status is analyzed. These are correlated with factors that are used in an earlier develloped prediction model

Conditions

Predictive Cancer Model

Outcome Measures

Primary Outcomes (1)

• survival after diagnosis of spinal metastasis

  survival after diagnosis of spinal metastasis

  minimal 6 months after inclusion

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

adult with a known or unknown malignancy presenting with symptomatic spinal metastasis

You may qualify if:

• patients with spinal spinal metastasis
• symptomatic
• adult
• informed consent

You may not qualify if:

• not understanding informed consent

Sponsors & Collaborators

• Radboud University Medical Center: lead

Study Sites (1)

Radboud University Nijmegen Medical Center

Nijmegen, Gelderland, 6500 HB, Netherlands

Location

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 8, 2024
• First Posted: May 13, 2024
• Study Start: January 1, 2021
• Primary Completion: January 1, 2024
• Study Completion: May 1, 2024
• Last Updated: May 13, 2024

Record last verified: 2024-05

Locations

NL (1)